Abciximab Reopro

Another antiadhesion antibody strategy in stroke therapy targets platelets. By impeding platelet aggregation, antibodies to platelets could have a role in preventing additional ischemic injury during reperfusion, as well as in potentiating thrombolytic action. Such an antiplatelet drug, abciximab (Reopro; Eli Lilly and Company), is currently in clinical stroke treatment trials. This drug is already in use in association with Phase 3 coronary angioplasty and stenting. A 400-patient Phase 2 randomized trial, with treatment started within 6 hr of stroke onset, was recently completed. A trend was observed toward higher symptomatic hemorrhage rates in the Reopro group (4%) versus placebo (1%), p = 0.09 (29). No significant differences were seen in efficacy outcome measures. A Phase 3 trial is planned.

Metabolism Masterclass

Metabolism Masterclass

Are You Sick And Tired Of All The Fat-Burning Tricks And Trends That Just Don’t Deliver? Well, Get Set To Discover The Easy, Safe, Fast, And Permanent Way To Mega-Charge Your Metabolism And Lose Excess Fat Once And For All! This Weight Blasting Method Is Easy AND Natural… And Will Give You The Hot Body And Killer Energy Levels You’ve Been Dreaming Of.

Get My Free Ebook

Post a comment